Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib - PubMed (original) (raw)
. 2018 Sep;40(3):1525-1532.
doi: 10.3892/or.2018.6552. Epub 2018 Jul 10.
Affiliations
- PMID: 30015938
- DOI: 10.3892/or.2018.6552
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib
Yuezhao Huang et al. Oncol Rep. 2018 Sep.
Abstract
Sorafenib resistance is one of the major factors affecting the prognosis of patients with hepatocellular carcinoma (HCC). Increasing evidence has indicated that certain traditional medicines can enhance the sensitivity of cancer cells to sorafenib. Berberine, an isoquinoline alkaloid, has been demonstrated to possess antitumor properties against various malignancies. However, the synergistic effect of the combination of berberine and sorafenib in HCC remains unknown. The aim of the present study was to determine the effects of berberine and sorafenib combination on the growth of liver cancer cells. Initially, it was observed that the combination of sorafenib and berberine exerted a synergistic inhibitory effect on the proliferation of SMMC‑7721 and HepG2 cells in a dose‑ and time‑dependent manner by an MTS assay. Edu staining and colony formation assays also revealed that the combination of 100 µM berberine and 4 µM sorafenib exhibited a significant anti‑proliferation effect on SMMC‑7721 and HepG2 cells. Furthermore, western blotting assay indicated that the expressions levels of cleaved poly(ADP‑ribose) polymerase and cleaved caspase‑3 increased, while those of the anti‑apoptotic protein B‑cell lymphoma 2 and vascular endothelial growth factor decreased. To the best of our knowledge, this is the first study to demonstrate that berberine sensitized liver cancer cells to sorafenib treatment. These results suggest that berberine combined with sorafenib is able to inhibit the proliferation of liver cancer cells and induce apoptosis, which provides evidence for further clinical investigation in HCC patients with sorafenib resistance.
Similar articles
- Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T. You A, et al. J Hematol Oncol. 2016 Mar 8;9:20. doi: 10.1186/s13045-016-0253-6. J Hematol Oncol. 2016. PMID: 26957312 Free PMC article. - Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y, Xu X, Zhang L, Zhang Y. Yan Y, et al. Biomed Pharmacother. 2017 Apr;88:395-402. doi: 10.1016/j.biopha.2017.01.077. Epub 2017 Jan 22. Biomed Pharmacother. 2017. PMID: 28122304 - Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N, Takei Y, Nobori T, Ito M. Nojiri K, et al. Int J Oncol. 2013 Jan;42(1):101-8. doi: 10.3892/ijo.2012.1676. Epub 2012 Oct 24. Int J Oncol. 2013. PMID: 23123700 - A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs.
Sun Y, Xun K, Wang Y, Chen X. Sun Y, et al. Anticancer Drugs. 2009 Oct;20(9):757-69. doi: 10.1097/CAD.0b013e328330d95b. Anticancer Drugs. 2009. PMID: 19704371 Review. - [Research Progress on the Role of Berberine in Hematologic Malignancies and Its Related Mechanisms --Review].
Cao YQ, Sun C, Li JY, Zhou X. Cao YQ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):639-642. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.048. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024. PMID: 38660879 Review. Chinese.
Cited by
- Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.
Sun L, He M, Li F, Wu D, Zheng P, Zhang C, Liu Y, Liu D, Shan M, Yang M, Ma Y, Lian J, Xiong H. Sun L, et al. Hepatol Commun. 2024 Mar 29;8(4):e0405. doi: 10.1097/HC9.0000000000000405. eCollection 2024 Apr 1. Hepatol Commun. 2024. PMID: 38573832 Free PMC article. - Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma.
Machado ART, Tuttis K, Santos PWDS, Aissa AF, Antunes LMG. Machado ART, et al. Pharmaceutics. 2022 Nov 24;14(12):2582. doi: 10.3390/pharmaceutics14122582. Pharmaceutics. 2022. PMID: 36559076 Free PMC article. - Berberine as a Potential Anticancer Agent: A Comprehensive Review.
Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Emran TB, Mitra S, Khan Z, Alhumaydhi FA, Aljohani ASM, Khan I, Rahman MM, Jeandet P, Gondal TA. Rauf A, et al. Molecules. 2021 Dec 4;26(23):7368. doi: 10.3390/molecules26237368. Molecules. 2021. PMID: 34885950 Free PMC article. Review. - Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs.
Wang K, Yu G, Lin J, Wang Z, Lu Q, Gu C, Yang T, Liu S, Yang H. Wang K, et al. Front Pharmacol. 2021 Jun 17;12:632201. doi: 10.3389/fphar.2021.632201. eCollection 2021. Front Pharmacol. 2021. PMID: 34220494 Free PMC article. - Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways.
Almatroodi SA, Alsahli MA, Rahmani AH. Almatroodi SA, et al. Molecules. 2022 Sep 10;27(18):5889. doi: 10.3390/molecules27185889. Molecules. 2022. PMID: 36144625 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials